127 related articles for article (PubMed ID: 27395799)
1. A comparison of two semi-mechanistic models for prolactin release and prediction of receptor occupancy following administration of dopamine D2 receptor antagonists in rats.
Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
Eur J Pharmacol; 2016 Oct; 789():202-214. PubMed ID: 27395799
[TBL] [Abstract][Full Text] [Related]
2. Modeling of prolactin response following dopamine D
Taneja A; Vermeulen A; Huntjens DRH; Danhof M; De Lange ECM; Proost JH
Pharmacol Res Perspect; 2017 Dec; 5(6):. PubMed ID: 29226628
[TBL] [Abstract][Full Text] [Related]
3. Summary data of potency and parameter information from semi-mechanistic PKPD modeling of prolactin release following administration of the dopamine D2 receptor antagonists risperidone, paliperidone and remoxipride in rats.
Taneja A; Vermeulen A; Huntjens DR; Danhof M; De Lange EC; Proost JH
Data Brief; 2016 Sep; 8():1433-7. PubMed ID: 27617278
[TBL] [Abstract][Full Text] [Related]
4. Optimization of maintenance therapy of Risperidone with CYP2D6 genetic polymorphisms through an extended translational framework-based prediction of target occupancies/clinical outcomes.
Li HQ; Xu JY; Gao YY; Jin L
Pharmacol Res; 2018 Nov; 137():135-147. PubMed ID: 30281999
[TBL] [Abstract][Full Text] [Related]
5. Using pharmacokinetic-pharmacodynamic modelling as a tool for prediction of therapeutic effective plasma levels of antipsychotics.
Olsen CK; Brennum LT; Kreilgaard M
Eur J Pharmacol; 2008 Apr; 584(2-3):318-27. PubMed ID: 18325493
[TBL] [Abstract][Full Text] [Related]
6. Physiologically Based Modeling Approach to Predict Dopamine D2 Receptor Occupancy of Antipsychotics in Brain: Translation From Rat to Human.
Wong YC; Centanni M; de Lange ECM
J Clin Pharmacol; 2019 May; 59(5):731-747. PubMed ID: 30676661
[TBL] [Abstract][Full Text] [Related]
7. Comparison of the agonist-antagonist interaction model and the pool model for the effect of remoxipride on prolactin.
Ma G; Friberg LE; Movin-Osswald G; Karlsson MO
Br J Clin Pharmacol; 2010 Dec; 70(6):815-24. PubMed ID: 21175437
[TBL] [Abstract][Full Text] [Related]
8. Development of a population pharmacokinetic model to predict brain distribution and dopamine D2 receptor occupancy of raclopride in non-anesthetized rat.
Wong YC; Ilkova T; van Wijk RC; Hartman R; de Lange ECM
Eur J Pharm Sci; 2018 Jan; 111():514-525. PubMed ID: 29106979
[TBL] [Abstract][Full Text] [Related]
9. Mechanism-based PK-PD model for the prolactin biological system response following an acute dopamine inhibition challenge: quantitative extrapolation to humans.
Stevens J; Ploeger BA; Hammarlund-Udenaes M; Osswald G; van der Graaf PH; Danhof M; de Lange EC
J Pharmacokinet Pharmacodyn; 2012 Oct; 39(5):463-77. PubMed ID: 22791078
[TBL] [Abstract][Full Text] [Related]
10. An agonist-antagonist interaction model for prolactin release following risperidone and paliperidone treatment.
Friberg LE; Vermeulen AM; Petersson KJ; Karlsson MO
Clin Pharmacol Ther; 2009 Apr; 85(4):409-17. PubMed ID: 19109590
[TBL] [Abstract][Full Text] [Related]
11. Pharmacokinetic-pharmacodynamic modeling of the D₂ and 5-HT (2A) receptor occupancy of risperidone and paliperidone in rats.
Kozielska M; Johnson M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2012 Jul; 29(7):1932-48. PubMed ID: 22437487
[TBL] [Abstract][Full Text] [Related]
12. Prolactin release after remoxipride by an integrated pharmacokinetic-pharmacodynamic model with intra- and interindividual aspects.
Movin-Osswald G; Hammarlund-Udenaes M
J Pharmacol Exp Ther; 1995 Aug; 274(2):921-7. PubMed ID: 7636755
[TBL] [Abstract][Full Text] [Related]
13. Revealing the Neuroendocrine Response After Remoxipride Treatment Using Multi-Biomarker Discovery and Quantifying It by PK/PD Modeling.
van den Brink WJ; Wong YC; Gülave B; van der Graaf PH; de Lange EC
AAPS J; 2017 Jan; 19(1):274-285. PubMed ID: 27785749
[TBL] [Abstract][Full Text] [Related]
14. Effects of remoxipride and raclopride on prolactin release from clonal pituitary tumour cells.
Nilsson CL; Eriksson E
Pharmacol Toxicol; 1995 Jan; 76(1):85-8. PubMed ID: 7753765
[TBL] [Abstract][Full Text] [Related]
15. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models.
Natesan S; Reckless GE; Nobrega JN; Fletcher PJ; Kapur S
Neuropsychopharmacology; 2006 Sep; 31(9):1854-63. PubMed ID: 16319908
[TBL] [Abstract][Full Text] [Related]
16. Target-Site Investigation for the Plasma Prolactin Response: Mechanism-Based Pharmacokinetic-Pharmacodynamic Analysis of Risperidone and Paliperidone in the Rat.
Shimizu S; den Hoedt SM; Mangas-Sanjuan V; Cristea S; Geuer JK; van den Berg DJ; Hartman R; Bellanti F; de Lange EC
Drug Metab Dispos; 2017 Feb; 45(2):152-159. PubMed ID: 27836941
[TBL] [Abstract][Full Text] [Related]
17. Translational Modeling in Schizophrenia: Predicting Human Dopamine D2 Receptor Occupancy.
Johnson M; Kozielska M; Pilla Reddy V; Vermeulen A; Barton HA; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2016 Apr; 33(4):1003-17. PubMed ID: 26718955
[TBL] [Abstract][Full Text] [Related]
18. Slow dissociation of partial agonists from the D₂ receptor is linked to reduced prolactin release.
Carboni L; Negri M; Michielin F; Bertani S; Fratte SD; Oliosi B; Cavanni P
Int J Neuropsychopharmacol; 2012 Jun; 15(5):645-56. PubMed ID: 21733233
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
20. Mechanism-based pharmacokinetic-pharmacodynamic modeling of the dopamine D2 receptor occupancy of olanzapine in rats.
Johnson M; Kozielska M; Pilla Reddy V; Vermeulen A; Li C; Grimwood S; de Greef R; Groothuis GM; Danhof M; Proost JH
Pharm Res; 2011 Oct; 28(10):2490-504. PubMed ID: 21647790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
